Mr. Rashid Bux reports

JAPAN PATENT OFFICE (JPO) ISSUED BIOMARK PATENT WITH CLAIMS COVERING ITS LUNG CANCER URINE BASED LIQUID BIOPSY ASSAY

The Japan Patent Office (JPO) has issued Biomark Diagnostics Inc. divisional patent application No. 7311659 titled "Methods of detecting lung cancer" using urine biomarkers. The issued patent belongs to a larger family of patents on the company's biomarker panel for detecting lung cancer.

"We are excited to expand our patent portfolio by offering clinicians and patients another more convenient and non-invasive option to detect lung cancer using novel and urine-based biomarkers. This robust panel of biomarkers demonstrates the company's technological capabilities in accelerating translational science in the dynamic field of metabolomics. Over the years, the company has successfully developed highly sensitive assays using saliva, plasma and urine mediums. In Japan approximately 125,000 new cases of lung cancer are reported annually," said Rashid Bux, chief executive officer and president of Biomark. He further adds: "Biomark is proud to expand its patent assets in its cancer diagnostic portfolio. We anticipate more announcements in the upcoming quarters related to our patent status."

According to the Market Data Forecast report, the cancer diagnostic market in Asia Pacific was valued at $30-billion (U.S.) in 2022 and is expected to grow at a compound annual growth rate of 9.1 per cent, reaching $47-billion (U.S.) by 2027, driven by higher chronic cancer cases and increasing demand for minimally invasive tests. Biomark's patent estate creates shareholder value by giving the company an opportunity to tap into this vast cancer diagnostic market.

About Biomark Diagnostics Inc.

Biomark is a liquid biopsy company developing a molecular diagnostics technology platform that leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improving cancer prognosis by allowing physicians to detect carcinomas in the presymptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. While the company's current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has plans to expand into other hard-to-detect and hard-to-treat cancers such as brain, ovarian and pancreatic.

We seek Safe Harbor.